To include your compound in the COVID-19 Resource Center, submit it here.

Boehringer discontinues PDE-9A inhibitor for AD

Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE